iron deficiency anemia epidemiology forecast insight

DelveInsight’s ‘Iron Deficiency Anemia (IDA)- Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the IDA across the several selected cancer types, historical and forecasted IDA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

IDA Understanding

Anemia is a condition that occurs when the quantity of red blood cells (RBCs) or hemoglobin concentration within them is lower than usual. Hemoglobin is required to transport oxygen, and if the patient has too few or malformed RBCs or not enough hemoglobin, the blood’s capacity to transport oxygen to the body’s tissues will be reduced.

Anemia is majorly characterized by a low number of RBCs and can cause weariness, shortness of breath, pallor, and weakness. RBC size, chronicity, and etiology are used to classify subtypes. Blood loss and decreased RBC production as observed in iron deficiency or increased RBC breakdown in hemolysis can all cause anemia. Iron deficiency has been estimated as the major cause of anemia.

The most common type of anemia is Iron Deficiency Anemia (IDA), which happens when the body does not have enough iron. Iron is required to produce hemoglobin in the body. An insufficient amount of iron in the blood makes it difficult for oxygen to reach the entire body. Depending upon the amount of iron present, IDA can be classified into mild, moderate, and severe categories. Patients suffering from mild and moderate forms of the disease generally do not showcase any signs or symptoms. However, patients suffering from a severe form report symptoms like fatigue or tiredness, shortness of breath, or chest pain.

IDA is characterized by a lack of iron; this can be majorly due to low consumption of iron. Other causes of IDA include blood loss, the inability of the patient’s body to absorb iron, blood loss, any other comorbid condition, and others.

For IDA diagnosis, the doctor generally suggests a physical examination as well as recommends several blood tests. A complete blood count test is the preferred test to check the number of normal blood cells, iron, and the amount of ferritin present in the body.

Epidemiology Perspective by DelveInsight

The IDA epidemiology division provides the insights about historical and current indication wise eligible patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted IDA epidemiology [segmented as Total prevalent cases of IDA, Total diagnosed prevalent cases of IDA, Total IDA cases by gender, Total IDA cases by pathology, Severity specific diagnosed cases of IDA, and Total Treated cases of IDA] scenario of IDA in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2021 to 2034.

Country Wise- IDA Epidemiology

• In 2020, the total prevalent cases of IDA were 30,829,734 in the 7MM. The United States, in the same year, accounted for 9,313,895 cases. According to DelveInsight's analysis, Japan had the highest prevalence of IDA cases in the 7MM, accounting for approximately 39% of the total 7MM cases in 2020.
• IDA is often underdiagnosed and undertreated, as some people may not have any symptoms at first. In the EU-5 countries, the total diagnosed prevalent cases of IDA were 4,277,646 in 2020. Many programs have been launched in an attempt to minimize the prevalence of IDA in the Western world. Screening, health education, iron fortification of food, and increased usage of iron-rich baby formula are among them.
• Females are more likely to be afflicted by IDA than men. In 2020, the total IDA cases in women health were estimated around 2,060,787 in the 7MM. Among all the pathology related cause of IDA, IDA in chronic kidney disease have the highest patient pool in 2020.
• When a patient is diagnosed with IDA, an iron-rich diet and oral iron supplements can help treat the majority of mild-to-moderate IDA cases. In the 7MM, it is accessed that 9,266,923 cases received first-line oral therapies. Some of the patients who have received first-line oral treatments fail and move to second-line oral medications such as Feraccru (Accrufer) and Auryxia (Riona). Moreover, some proportion of patients who receive second-line oral treatments and who have severe IDA will proceed to IV iron therapy.

Scope of the Report

• The IDA report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
• The IDA Report and Model provide an overview of the risk factors and global trends of IDA in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of IDA in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of IDA.
• The report provides the segmentation of the IDA epidemiology by total prevalent cases in the 7MM.
• The report provides the segmentation of the IDA epidemiology by diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the IDA epidemiology by gender-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the IDA epidemiology by pathology-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the severity-specific diagnosed cases of IDA in the 7MM.
• The report provides the segmentation of the IDA epidemiology by treated cases of IDA in the 7MM.

Report Highlights

• 10-Year Forecast of IDA epidemiology
• 7MM Coverage
• Epidemiology segmentation

KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to IDA?
• What are the key findings pertaining to the IDA epidemiology across the 7MM and which country will have the highest number of prevalent cases of IDA during the study period (2021-2034)?
• What would be the total number of patients of IDA across the 7MM during the study period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2021-2034)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2021-2034)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of IDA?

Reasons to buy

The IDA Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global IDA market
• Quantify patient populations in the global IDA market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for IDA therapeutics in each of the markets covered
• The IDA epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The IDA Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Factors driving growth in a specific patient population